Clinical Trials on Stage IV Esophageal Squamous Cell Carcinoma

Total 5536 results

The First Affiliated Hospital of Soochow University
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma

China
Keio University

Recruiting

Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel

Esophageal Squamous Cell Carcinoma

Japan
National Cancer Center, Japan

Recruiting

A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC (ARMADILLO)

Esophageal Squamous Cell Carcinoma

Japan
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma

Esophageal Squamous Cell Carcinoma

China
Wuhan University

Recruiting

The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer

Esophageal Squamous Cell Carcinoma

China
Henan Cancer Hospital

Recruiting

Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903) (HCHTOG1903)

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (SKYSCRAPER-07)

Esophageal Squamous Cell Carcinoma

United States, France, Spain, Australia, Korea, Republic of, Argentina, Belgium, China, Portugal, Taiwan, Japan, Germany, Poland, Thailand, United Kingdom, Switzerland, Turkey, Russian Federation, Morocco, Greece, Italy, New Zealand, South Africa and more
Sun Yat-sen University

Active, not recruiting

Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Tianjin Medical University Cancer Institute and...

Completed

The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Peking Union Medical College Hospital

Completed

Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Fudan University

Completed

Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Active, not recruiting

Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)

Esophageal Squamous Cell Carcinoma

China
Yuhong Li

Completed

Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
NYU Langone Health

Terminated

Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

United States
Peking University

Withdrawn

Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Completed

Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment

Esophageal Squamous Cell Carcinoma

China
Guangzhou Institute of Respiratory Disease
Jiangsu HengRui Medicine Co., Ltd.; BGI-Shenzhen

Completed

Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma | Immunotherapy

China
Fudan University

Unknown

A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCC

Esophageal Squamous Cell Carcinoma

China
National Cancer Institute (NCI)

Completed

A Pilot for a Case-Control Study of Esophageal Squamous Cell Carcinoma in Western Kenya

Esophageal Squamous Cell Carcinoma

Kenya
Samsung Medical Center

Withdrawn

Genome-wide Association Study

Esophageal Squamous Cell Carcinoma

Korea, Republic of
Peking University

Unknown

Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo) (ECMTPneo)

Esophageal Squamous Cell Carcinoma

China
Fudan University

Completed

Study of S-1 in Combination With Radiotherapy in Esophageal Cancer

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC

Esophageal Squamous Cell Carcinoma

China
Fudan University
Fujian Cancer Hospital; Affiliated Hospital of Jiangnan University; First Affiliated... and other collaborators

Completed

A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma

Esophageal Squamous Cell Carcinoma

China
Zhejiang Cancer Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University

Completed

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients (nabPCESCC)

Esophageal Squamous Cell Carcinoma

China
Fudan University
Zhejiang Cancer Hospital; The First Affiliated Hospital of Anhui Medical University and other collaborators

Unknown

Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0

Esophageal Squamous Cell Carcinoma

China
Mayo Clinic

Recruiting

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA)

Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 and other conditions

United States
Emory University
Bristol-Myers Squibb; Brooklyn ImmunoTherapeutics, LLC

Withdrawn

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma | Stage II Oral Cavity Squamous Cell...

United States
Samsung Medical Center

Completed

Phase II Trial of XP Versus XG in Advanced Esophageal Squamous Cell Carcinoma

Advanced or Recurrent Esophageal Squamous Cell Carcinoma

Korea, Republic of
Yonsei University

Unknown

A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus

Squamous Cell Carcinoma of Esophagus

Korea, Republic of
Eli Lilly and Company

Completed

A Phase 1 Study in Participants With Advanced Cancer

Carcinoma, Non-Small-Cell Lung | Advanced Cancer | Anal Squamous Cell Carcinoma | Squamous Cell Carcinoma | Carcinoma, Squamous Cell of Head and Neck | Lung Squamous Cell Carcinoma Stage IV

United States
Sun Yat-sen University

Recruiting

Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.

Esophageal Squamous Cell Carcinoma

China
Fudan University

Recruiting

Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma

Esophageal Squamous Cell Carcinoma

China
Army Medical Center of PLA

Recruiting

A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy | Esophageal Squamous Cell Carcinoma

China
Sun Yat-sen University

Recruiting

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

Efficacy | Toxicity | Esophageal Squamous Cell Carcinoma

China
Guangdong Provincial People's Hospital

Recruiting

Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC.

Chemotherapy | Esophageal Squamous Cell Carcinoma | Immunotherapy

China
The First Affiliated Hospital of Soochow University

Recruiting

Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal Flora

Esophageal Squamous Cell Carcinoma | Intestinal Flora

China
Fudan University
Fujian Cancer Hospital; Jiangsu Cancer Institute & Hospital; Ningbo No.2 Hospital and other collaborators

Recruiting

Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)

Esophageal Squamous Cell Carcinoma | Survival | Chemoradiotherapy

China
Second Affiliated Hospital, School of Medicine,...

Active, not recruiting

Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy | Esophageal Squamous Cell Carcinoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

Locally Advanced Unresectable Esophageal Squamous Carcinoma

China
Zhejiang Cancer Hospital

Not yet recruiting

Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy

Adjuvant Radiotherapy

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy | Esophageal Squamous Cell Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma

Esophagus Cancer

China
Sun Yat-sen University

Recruiting

Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC

Esophageal Squamous Cell Carcinoma | Oligometastatic Disease

China
Jiangsu Cancer Institute & Hospital

Recruiting

Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC (LATE)

Chemoradiation | Esophageal Squamous Cell Carcinoma | Tislelizumab

China
Fifth Affiliated Hospital, Sun Yat-Sen University

Recruiting

Quantitative Evaluation of Metastatic Lymph Nodes With Dynamic 18F-FDG PET/CT in Patients With ESCC

Esophageal Squamous Cell Carcinoma | Positron Emission Tomography

China

Clinical Trials on Stage IV Esophageal Squamous Cell Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations